Bayer to Acquire Vividion for ~$2B

Share this


Bayer to Acquire Vividion for ~$2B


  • Vividion to receive $1.5B up front & $500M milestone while Bayer to get full rights to Vividion’s discovery platform which consists of chemoproteomic screening technology- a data portal- and a chemistry library. The transaction is expected to close in Q3’21
  • The acquisition will strengthen Bayer’s drug discovery capabilities & expand it into new modalities. The acquisition will also increase the value of Vividion’s pipeline
  • Vividion’s technology has the potential to expand into additional indications as it is already proved in oncology & immune-related diseases in preclinical studies

| Ref: Bayer | Image: The Business Journals

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions